Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma

Leukemia

Volumn 21, Issue 1, 2007, Pages 158-163

  Arnulf, B ^a   Lecourt, S ^b   Soulier, J ^c   Ternaux, B ^a   Lacassagne, M Noelle ^a   Crinquette, A ^c   Dessoly, J ^c   Sciaini, A K ^c   Benbunan, M ^a   Chomienne, C ^d   Fermand, J P ^a   Marolleau, J P ^e   Larghero, J ^a,d  

^a SAINT LOUIS HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Laboratoire Central d'Hematologie   (France)

^d INSERM   (France)

^e AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ADIPOCYTE; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER PATIENT; CELL DIFFERENTIATION; CELL FUNCTION; CHROMOSOME ANALYSIS; CLONAL VARIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HEMATOPOIESIS; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MARKER GENE; MESENCHYMAL STEM CELL; MULTIPLE MYELOMA; OSTEOCYTE; PATHOGENESIS; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL;

EID: 33845513318     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404466     Document Type: Article

References (29)

1. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: Clinical applications. Blood 2004; 104: 607-618.
2. Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003; 97: 2440-2452.
3. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998; 91: 3-21.
4. Dalton WS. The tumor microenvironment: Focus on myeloma. Cancer Treat Rev 2003; 29 (Suppl 1): 11-19.
5. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and Interleukin-6: A potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006; 24: 986-991.
6. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD et al. Multilineage potential of adult mesenchymal stem cells. Science 1999; 284: 143-147.
7. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71-74.
8. Silva Jr WA, Covas DT, Panepucci RA, Proto-Siqueira R, Siufi JL, Zanette DL et al. The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells 2003; 21: 661-669.
9. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843.
10. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619-4621.
11. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305: 33-41.
12. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372.
13. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126.
14. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
15. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000; 355: 248-250.
16. Epstein J, Yaccoby S. Consequences of interactions between the bone marrow stroma and myeloma. Hematol J 2003; 4: 310-314.
17. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998; 92: 3025-3034.
18. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11-20.
19. Yeh SP, Chang JG, Lo WJ, Liaw YC, Lin CL, Lee CC et al. Induction of CD45 expression on bone marrow-derived mesenchymal stem cells. Leukemia 2006; 20: 894-896.
20. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82: 3712-3720.
21. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 917-924.
22. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991; 77: 2688-2693.
23. Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 2001; 91: 1219-1230.
24. Potter M. Neoplastic development in plasma cells. Immunol Rev 2003; 194: 177-195.
25. Arnulf B, Bengoufa D, Sarfati E, Toubert ME, Meignin V, Brouet JC et al. Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: A prospective study. Arch Intern Med 2002; 162: 464-467.
26. Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004; 351: 250-259.
27. Rigolin GM, Fraulini C, Ciccone M, Mauro E, Bugli AM, De Angeli C et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 2006; 107: 2531-2535.
28. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumor-cell plasticity: Lessons from melanoma. Nat Rev Cancer 2003; 3: 411-421.
29. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.